These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 18231106)

  • 21. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.
    Thompson R; Eastman A
    Br J Clin Pharmacol; 2013 Sep; 76(3):358-69. PubMed ID: 23593991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer?
    Kuntz K; O'Connell MJ
    Cancer Biol Ther; 2009 Aug; 8(15):1433-9. PubMed ID: 19574738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
    Zabludoff SD; Deng C; Grondine MR; Sheehy AM; Ashwell S; Caleb BL; Green S; Haye HR; Horn CL; Janetka JW; Liu D; Mouchet E; Ready S; Rosenthal JL; Queva C; Schwartz GK; Taylor KJ; Tse AN; Walker GE; White AM
    Mol Cancer Ther; 2008 Sep; 7(9):2955-66. PubMed ID: 18790776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
    Zenvirt S; Kravchenko-Balasha N; Levitzki A
    Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Checkpoint kinase inhibitors: a patent review (2009 - 2010).
    Lainchbury M; Collins I
    Expert Opin Ther Pat; 2011 Aug; 21(8):1191-210. PubMed ID: 21599421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Turning off the G2 DNA damage checkpoint.
    Calonge TM; O'Connell MJ
    DNA Repair (Amst); 2008 Feb; 7(2):136-40. PubMed ID: 17851138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of Rad3 and Chk1 protein kinases defines different checkpoint responses.
    Martinho RG; Lindsay HD; Flaggs G; DeMaggio AJ; Hoekstra MF; Carr AM; Bentley NJ
    EMBO J; 1998 Dec; 17(24):7239-49. PubMed ID: 9857181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
    Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
    Pan Y; Ren KH; He HW; Shao RG
    Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
    Sakurikar N; Thompson R; Montano R; Eastman A
    Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage.
    Sturgeon CM; Knight ZA; Shokat KM; Roberge M
    Mol Cancer Ther; 2006 Apr; 5(4):885-92. PubMed ID: 16648558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of cell death and induction of G2 arrest accumulation in human ovarian clear cells by HNF-1β transcription factor: chemosensitivity is regulated by checkpoint kinase CHK1.
    Shigetomi H; Sudo T; Shimada K; Uekuri C; Tsuji Y; Kanayama S; Naruse K; Yamada Y; Konishi N; Kobayashi H
    Int J Gynecol Cancer; 2014 Jun; 24(5):838-43. PubMed ID: 24804869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response.
    Luo Y; Leverson JD
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):333-42. PubMed ID: 15877529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
    Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
    Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting checkpoint kinase 1 in cancer therapeutics.
    Tse AN; Carvajal R; Schwartz GK
    Clin Cancer Res; 2007 Apr; 13(7):1955-60. PubMed ID: 17404075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability.
    Chen Y; Poon RY
    Front Biosci; 2008 May; 13():5016-29. PubMed ID: 18508566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of checkpoint kinase 1 abrogates G2/M checkpoint activation and promotes apoptosis under heat stress.
    Furusawa Y; Iizumi T; Fujiwara Y; Zhao QL; Tabuchi Y; Nomura T; Kondo T
    Apoptosis; 2012 Jan; 17(1):102-12. PubMed ID: 22080164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.